Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: A retrospective US claims database analysis

Current Medical Research and Opinion

Volumn 29, Issue 12, 2013, Pages 1647-1656

  Bergvall, Niklas ^a   Makin, Charles ^b   Lahoz, Raquel ^a   Agashivala, Neetu ^a   Pradhan, Ashish ^a   Capkun, Gorana ^a   Petrilla, Allison ^b   Karkare, Swapna U ^b   Balderston McGuiness, Catherine ^b   Korn, Jonathan R ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b IQVIA   (United States)

Author keywords

Disease modifying therapies; Fingolimod; Glatiramer acetate; Interferon; Multiple sclerosis; Relapse

Indexed keywords

4 AMINOPYRIDINE; BETA1A INTERFERON; CORTICOSTEROID; FINGOLIMOD; GLATIRAMER; INTERFERON; INTERFERON BETA SERINE; NATALIZUMAB;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DATA BASE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICATION COMPLIANCE; MULTIPLE SCLEROSIS; PROBABILITY; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK REDUCTION; SYMPTOMATOLOGY; TREATMENT OUTCOME; UNITED STATES;

ADULT; DATABASES, FACTUAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSURANCE CLAIM REVIEW; INTERFERONS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PEPTIDES; PROPYLENE GLYCOLS; RECURRENCE; RETROSPECTIVE STUDIES; SPHINGOSINE; UNITED STATES;

EID: 84888579674     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.847411     Document Type: Article

References (36)

1. National Multiple Sclerosis Society. MS prevalence. Available at: http://www.nationalmssociety.org/about-the-society/ms-prevalence/index.aspx [Last accessed 22 Jun 2013]
2. Bainbridge JL, Rieckmann P. Multiple sclerosis. In: DiPiro JT, Talbert R, Yee G, Matzke G, eds. Pharmacotherapy: a pathophysiologic approach. New York: McGraw-Hill Medical, 2008:913-26
3. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31 (Pubitemid 34304266)
4. Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006;13:700-22 (Pubitemid 44143944)
5. Rolak LA. Multiple sclerosis: it's not the disease you thought it was. Clin Med Res 2003;1:57-60
6. Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med 2002;53: 285-302 (Pubitemid 34182821)
7. Richards RG, Sampson FC, Beard SM, et al. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002;6:1-73
8. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528-32 (Pubitemid 37505574)
9. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112(Pt 6):1419-28 (Pubitemid 20024212)
10. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11
11. Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med 2011;78:161-75
12. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655-61
13. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94 (Pubitemid 26100751)
14. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000;6: 255-66
15. Reynolds MW, Stephen R, Seaman C, et al. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ 2010;13:90-8
16. Clerico M, Barbero P, Contessa G, et al. Adherence to interferon-beta treatment and results of therapy switching. J Neurol Sci 2007;259:104-8 (Pubitemid 47031209)
17. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005;11:306-9 (Pubitemid 40775187)
18. Thone J, Ellrichmann G. Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits. Drug Healthc Patient Saf 2013;5:37-47
19. Calabresi PA, Goodin D, Jeffery D, et al. Efficacy and safety of fingolimod versus placebo: primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing-remitting multiple sclerosis. Abstract presented at the 28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis, 10-13 October 2012. Lyon, France. Abstract available at: http://registration.akm.ch/einsicht.php?XNABSTRACT-ID=156899&XNSPR ACHE-ID=2&XNKONGRESS-ID=171&XNMASKEN-ID=900 [last accessed 22 Jun 2013]
20. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
21. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
22. Agashivala N, Wu N, Abouzaid S, et al. Comparison of compliance to fingo-limod and other first-line disease modifying treatment among patients with multiple sclerosis. ACMP 2012 Education Conference, AMCP 2012 Education Conference, 3-5 October 2012, Cincinnati, OH, USA, 2012
23. Steinberg SC, Faris RJ, Chang CF, et al. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Investig 2010;30:89-100
24. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18:69-77
25. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol 2009;256:568-76
26. Ollendorf DA, Castelli-Haley J, Oleen-Burkey M. Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis. J Neurosci Nurs 2008;40:281-90
27. Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther 2011;28:51-61
28. Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ 2010;13:618-25
29. Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 2002;8:469-76
30. Graf C, Battisti WP, Bridges D, et al. Research methods & reporting. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ 2009;339:b4330, http://www.bmj.com/content/339/bmj. b4330
31. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-9 (Pubitemid 351289042)
32. Capkun-Niggli G, Lahoz R, Verdun E, et al. Medical and pharmacy claims-based algorithms for identifying relapses in patients with multiple sclerosis. ISPOR 16th Annual European Congress, 2-6 November 2013
33. D'Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 1993;32:382-7 (Pubitemid 24001924)
34. Roos LL, Stranc L, James RC, et al. Complications, comorbidities, and mortality: improving classification and prediction. Health Serv Res 1997;32:229-38, discussion 39-42
35. Roskell NS, Zimovetz EA, Rycroft CE, et al. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod. Curr Med Res Opin 2012;28:767-80
36. Agashivala N, Wu N, Abouzaid S, et al. Comparison of time to discontinuation among multiple sclerosis patients receiving fingolimod and other first-line disease modifying treatment. ECTRIMS 28th Congress of the European Committee, 10-13 October 2012